We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+8.81%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.12B
AUM Growth
+$515M
Cap. Flow
+$653M
Cap. Flow %
10.66%
Top 10 Hldgs %
53.58%
Holding
69
New
14
Increased
25
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$169M
2
NUVL
Nuvalent
NUVL
+$140M
3
OCUL icon
Ocular Therapeutix
OCUL
+$111M
4
GMAB icon
Genmab
GMAB
+$110M
5
VERA icon
Vera Therapeutics
VERA
+$55.4M

Top Sells

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$242M
2
CYTK icon
Cytokinetics
CYTK
+$125M
3
APLS
Apellis Pharmaceuticals
APLS
+$69.3M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$67.1M
5
MAZE
Maze Therapeutics
MAZE
+$33.9M

Sector Composition

Rank Sector Weight
1 Healthcare 79.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$1.28B 20.86%
10,000,000
– –
GH icon
2
Guardant Health
GH
$21.7B
$308M 5.04%
3,338,241
+538,241
+19% +$54M
IMVT icon
3
Immunovant
IMVT
$7.93B
$286M 4.68%
11,526,971
– –
TARS icon
4
Tarsus Pharmaceuticals
TARS
$2.58B
$253M 4.12%
3,600,000
+595,966
+20% +$41.6M
PCVX icon
5
Vaxcyte
PCVX
$7.81B
$250M 4.08%
4,300,000
+300,000
+8% +$16.3M
GPCR icon
6
Structure Therapeutics
GPCR
$3.41B
$206M 3.37%
4,279,848
+168,066
+4% +$11.5M
AXSM icon
7
Axsome Therapeutics
AXSM
$11.2B
$186M 3.04%
1,100,000
-50,000
-4% -$8.64M
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
$182M 2.98%
4,532,374
-3,217,626
-42% -$69.3M
OCUL icon
9
Ocular Therapeutix
OCUL
$1.79B
$167M 2.72%
19,686,282
+11,615,868
+144% +$111M
VERA icon
10
Vera Therapeutics
VERA
$2.3B
$165M 2.7%
4,106,067
+1,284,932
+46% +$55.4M
ALMS
11
Alumis Inc
ALMS
$3.6B
$149M 2.44%
+6,772,595
New +$169M
IONS icon
12
Ionis Pharmaceuticals
IONS
$8.6B
$146M 2.39%
1,950,000
+250,000
+15% +$19.7M
NUVL
13
DELISTED
Nuvalent
NUVL
$141M 2.3%
+1,376,324
New +$140M
ALKS icon
14
Alkermes
ALKS
$8.22B
$127M 2.07%
3,590,323
+1,590,323
+80% +$49.3M
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$125M 2.05%
3,158,041
+1,158,041
+58% +$29.6M
MLTX icon
16
MoonLake Immunotherapeutics
MLTX
$1.57B
$119M 1.95%
6,408,863
+1,798,792
+39% +$29.8M
MAZE
17
Maze Therapeutics
MAZE
$1.49B
$104M 1.7%
3,477,562
-768,878
-18% -$33.9M
ORKA
18
Oruka Therapeutics
ORKA
$5.82B
$99.8M 1.63%
2,034,203
-127,307
-6% -$4.42M
NRIX icon
19
Nurix Therapeutics
NRIX
$2.41B
$98.4M 1.61%
6,345,244
-691,211
-10% -$11.5M
GMAB icon
20
Genmab
GMAB
$17.7B
$98.3M 1.61%
+3,663,250
New +$110M
CYTK icon
21
Cytokinetics
CYTK
$10.5B
$90.6M 1.48%
1,374,320
-1,962,678
-59% -$125M
GRAL
22
GRAIL Inc
GRAL
$2.94B
$89M 1.45%
1,722,797
+700,000
+68% +$54.2M
LBRX
23
LB Pharmaceuticals
LBRX
$1.15B
$82.7M 1.35%
3,352,804
– –
MBX
24
MBX Biosciences
MBX
$3.14B
$82.3M 1.34%
2,757,569
-492,221
-15% -$16.7M
BCAX
25
Bicara Therapeutics
BCAX
$1.78B
$80.8M 1.32%
4,062,500
+1,448,496
+55% +$24.9M
1
2 3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Deep Track Capital held 69 positions worth $6.12B, up 9.2% from $5.61B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deep Track Capital deployed $653M of net new capital in Q1 2026, opening 14 new positions and adding to 25 existing holdings. Its largest new stake was Alumis Inc: 6,772,595 shares worth $149M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $125M trimmed.

  • Deep Track Capital's largest Q1 2026 buy was Alumis Inc: 6,772,595 shares worth $149M.
  • Deep Track Capital added most to Ocular Therapeutix in Q1 2026, an estimated $111M increase.
  • Deep Track Capital's biggest Q1 2026 reduction was Cytokinetics, cutting an estimated $125M.
  • Deep Track Capital fully exited Dynavax Technologies in Q1 2026, selling an estimated $242M.
  • Deep Track Capital's ten largest holdings make up 54% of its $6.12B portfolio in Q1 2026.
  • Deep Track Capital opened 14 new positions and closed 6 in Q1 2026.
  • Deep Track Capital's portfolio value rose 9.2% quarter-over-quarter to $6.12B.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.